Literature DB >> 12734315

Development of investigational radiation modifiers.

A Dimitrios Colevas1, J Martin Brown, Stephen Hahn, James Mitchell, Kevin Camphausen, C Norman Coleman.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12734315     DOI： 10.1093/jnci/95.9.646

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

1.  Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

Authors:  Qi Liu; Meng Wang; Ashley M Kern; Saman Khaled; Jing Han; Beow Y Yeap; Theodore S Hong; Jeff Settleman; Cyril H Benes; Kathryn D Held; Jason A Efstathiou; Henning Willers
Journal:  Mol Cancer Res       Date:  2015-02-09       Impact factor: 5.852

Review 2.  Decreasing the Toxicity of Radiation Therapy: Radioprotectors and Radiomitigators Being Developed by the National Cancer Institute Through Small Business Innovation Research Contracts.

Authors:  Kaveh Zakeri; Deepa Narayanan; Bhadrasain Vikram; Greg Evans; C Norman Coleman; Pataje G S Prasanna
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-12-21       Impact factor: 7.038

Review 3.  Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Authors:  Amanda J Walker; Sara R Alcorn; Amol K Narang; Katriana M Nugent; Aaron T Wild; Joseph M Herman; Phuoc T Tran
Journal:  Curr Probl Cancer       Date:  2013-10-05       Impact factor: 3.187

4.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

5.  Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.

Authors:  Apollina Goel; Angela Dispenzieri; Susan M Geyer; Suzanne Greiner; Kah-Whye Peng; Stephen J Russell
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

6.  Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.

Authors:  Steven H Lin; Henning Willers; Sunil Krishnan; Jann N Sarkaria; Michael Baumann; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-25       Impact factor: 8.013

7.  Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Authors:  Reshma Jagsi; Kent A Griffith; Jennifer R Bellon; Wendy A Woodward; Janet K Horton; Alice Ho; Felix Y Feng; Corey Speers; Beth Overmoyer; Michael Sabel; Anne F Schott; Lori Pierce
Journal:  J Clin Oncol       Date:  2018-03-20       Impact factor: 44.544

8.  Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.

Authors:  Jia Hu; Li Juan Chen; Li Liu; Xiang Chen; Ping Li Chen; Guang Yang; Wen Li Hou; Ming Hai Tang; Fan Zhang; Xian Huo Wang; Xia Zhao; Yu Quan Wei
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

9.  Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.

Authors:  Kaveh Zakeri; Deepa Narayanan; Pataje G S Prasanna; Bhadrasain Vikram; Jeffrey C Buchsbaum
Journal:  Radiat Res       Date:  2020-03-27       Impact factor: 2.841

Review 10.  Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.

Authors:  Sara Alcorn; Amanda J Walker; Nishant Gandhi; Amol Narang; Aaron T Wild; Russell K Hales; Joseph M Herman; Danny Y Song; Theodore L Deweese; Emmanuel S Antonarakis; Phuoc T Tran
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.